Background
Areterna offers Cap Analogs, NTPs, and Modified NTPs for mRNA synthesis. Our products have been tested and accepted by over 200 companies worldwide. One of these companies shared with us how they decided to use our products.
This company conducted a comparative study by performing In-Vitro-Transcription (IVT) using products from Areterna and two other predominant suppliers: Comp-1 and Comp-2.
Results
In the first IVT reaction, they used everything from Comp-1, including T7 Polymerase enzyme, NTPs, N1-Methyl-pseudo-UTP, and cap analog. The output they were interested in was Full-Length-Product (FLP) and yield. In IVT-1, they got 80% of Full-Length-Product (FLP) and 6.5 mg/mL yield. They then tried enzymes and NTPs from Comp-2, the %FLP was not as good as the first IVT, but the yield got better in one case. Finally, they tested Areterna’s NTPs and cap analogs in IVT-4 and IVT-5.
In both cases, the %FLP was as good as IVT-1, but the yield improved dramatically to 7.6mg/mL and 8.0mg/mL. Everything being equal, our novel Cap4 delivered great purity in terms of %FLP and superior yield at 8mg/mL.
Key Takeaways
Based on these data, the customer decided to use our NTPs, N1-Mehtyl-pUTP, and cap analogs.
To summarize,
- Our NTPs and cap analogs deliver high purity (%FLP) and high yield (IVT-4 vs. IVT-1)
- Our Cap4 offers higher yield than m7GpppAmG (IVT-5 vs. IVT-4)